Peter Nash
0000-0002-2571-788X
Griffith University
193 papers found
Refreshing results…
Long-Term Safety of Tocilizumab (Tcz) in Patients with Rheumatoid Arthritis (Ra) and a Mean Treatment Duration of 3.7 Years
Australian Economic Evaluation of Tocilizumab (Tcz) Monotherapy Vs. Adalimumab (Ada) Monotherapy in Patients with Rheumatoid Arthritis (Ra) Based On the Adacta Trial
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study
Tofacitinib, An Oral Janus Kinase Inhibitor: Patient Reported Outcomes in An Australian Phase 3 Rheumatoid Arthritis Study Population
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: AN Australian survey study
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose
Subcutaneous abatacept versus intravenous abatacept in patients with rheumatoid arthritis: Long-term data from the acquire trial
An immunochip-based interrogation of scleroderma susceptibility variants
Australian psoriasis treatment goals project
A survey study of methotrexate use by rheumatologists and their patients with rheumatoid arthritis
Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous loading dose
Tofacitinib (cp-690,550), an oral Janus Kinase Inhibitor: Pooled phase 3 analysis in an Australian Rheumatoid Arthritis Study Population
Subcutaneous abatacept: long-term data from the Acquire Trial
Safety profile of subcutaneous abatacept focusing On clinically relevant events in patients with rheumatoid arthritis and up to 4.5 years of exposure
Matrix: Mapping Australian Treatment Reality Involving Methotrexate (mtx), a Survey Study of Rheumatologists and Their Patients with Rheumatoid Arthritis (ra)
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study
Missing publications? Search for publications with a matching author name.